SPY445.87+3.37 0.76%
DIA352.85+3.84 1.10%
IXIC14,897.34+73.91 0.50%

Stifel Initiates Coverage On Intellia Therapeutics with Buy Rating, Announces Price Target of $173

Stifel analyst Dae Gon Ha initiates coverage on Intellia Therapeutics (NASDAQ:NTLA) with a Buy rating and announces Price Target of $173.

Benzinga · 09/24/2021 05:20
Stifel analyst Dae Gon Ha initiates coverage on Intellia Therapeutics (NASDAQ:NTLA) with a Buy rating and announces Price Target of $173.